Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Tidal Investments LLC

Tidal Investments LLC lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 60.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 15,351 shares of the medical equipment provider’s stock after buying an additional 5,764 shares during the period. Tidal Investments LLC’s holdings in Hologic were worth $1,250,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in HOLX. Prentiss Smith & Co. Inc. lifted its stake in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares in the last quarter. Covestor Ltd raised its holdings in shares of Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the period. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Empirical Finance LLC boosted its holdings in Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 147 shares during the period. Finally, Wedmont Private Capital grew its position in Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after acquiring an additional 162 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Evercore ISI boosted their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Finally, Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $89.50.

Insider Activity at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.75% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $71.47 on Thursday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $16.22 billion, a price-to-earnings ratio of 21.46, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96. Hologic, Inc. has a twelve month low of $70.24 and a twelve month high of $84.67. The business has a 50 day simple moving average of $78.84 and a 200-day simple moving average of $78.57.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.89 earnings per share. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.